Jang discusses the results of an open-label extension highlighting the comparative efficacy of this combination therapy versus standard-of-care ravulizumab.
Jun Ho Jang, MD, PhD
Advertisement
Jun Ho Jang, MD, PhD, is a professor in the division of hematology-oncology at the Samsung Medical Center.
Articles by Jun Ho Jang, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5